A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
← catalyst calendarNCT07400653 · readout in 419 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
1,044actual
Sites
183
Countries
Argentina, Bulgaria, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-24 | actual | When the study began enrolling |
| Primary completion | 2027-10-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-16 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight and/or Obesity
- Overweight
- Diabetes, Type 2
- Type 2 Diabetes
Interventions
- Drug: PF-08653944 — also filed as MET097
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from baseline in body weight
measured Baseline, Week 64
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed